Edward Rico, MD
Endocrinology, Diabetes & Metabolism · Terre Haute, INNPI 1477739423
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,106 of the $134,767 with a category attached, or 87.6%. Novo Nordisk accounts for 62.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $69,944 and has fallen 99.9% since, to $103 in 2025. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $287.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$84K
- AstraZeneca$20K
- Johnson & Johnson$14K
- Sanofi-aventis U.S. LLC$13K
- Lilly USA, LLC$396
- Medtronic$238
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$118,10688%
- Travel & lodging$9,1067%
- Food & beverage$7,4376%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 164 | $84,231 |
| AstraZeneca | 40 | $20,293 |
| Johnson & Johnson | 74 | $14,498 |
| Sanofi-aventis U.S. LLC | 32 | $12,989 |
| Lilly USA, LLC | 21 | $396 |
| Medtronic(2 entities) | 7 | $238 |
| Abbott | 16 | $214 |
| Insulet Corporation | 13 | $205 |
| Boehringer Ingelheim | 12 | $200 |
| Mannkind Corporation | 7 | $180 |
| Xeris Pharmaceuticals, Inc. | 9 | $170 |
| Amgen(2 entities) | 10 | $164 |
| AbbVie | 8 | $116 |
| Merck | 8 | $114 |
| Corcept Therapeutics | 6 | $102 |
| Antares Pharma, Inc. | 5 | $74 |
| IBSA Pharma Inc. | 4 | $72 |
| Clarus Therapeutics Inc. | 5 | $70 |
| Dexcom, Inc. | 4 | $63 |
| Recordati_rare_diseases_inc. | 4 | $63 |
| Tandem Diabetes Care, Inc. | 4 | $59 |
| Pfizer | 3 | $49 |
| Novartis | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Echosens North America, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Zealand Pharma US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,767 in reported general payments places this provider in the 90th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 322 | $371,013 |
| MounjaroTirzepatide | 122 | $135,635 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 37 | $125,872 |
| JardianceEmpagliflozin | 112 | $116,856 |
| TrulicityDulaglutide | 87 | $111,363 |
| Tresiba Flextouch U-100Insulin Degludec | 115 | $66,855 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 54 | $57,227 |
| JanuviaSitagliptin Phosphate | 44 | $48,985 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $48,745 |
| ForteoTeriparatide | 11 | $47,433 |
| Humalog Kwikpen U-100Insulin Lispro | 97 | $42,271 |
| FarxigaDapagliflozin Propanediol | 52 | $37,716 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $30,973 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $21,020 |
| Novolog FlexpenInsulin Aspart | 68 | $20,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $84,231 | $391,188354 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $396 | $302,185242 claims |
| Boehringer IngelheimJardiance, Tradjenta | $200 | $132,246129 claims |
| MerckJanuvia, Janumet Xr | $114 | $70,00564 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $12,989 | $57,22754 claims |
| AstraZenecaFarxiga | $20,293 | $37,71652 claims |
| Johnson & JohnsonInvokana | $14,498 | $18,43711 claims |
| AbbVieSynthroid | $116 | $12,048138 claims |
| IBSA Pharma Inc.Tirosint-Sol, Tirosint | $72 | $7,99938 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $4,329223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Terre Haute
- Isaiah PittmanTerre Haute$1.5M
- Mohammad AlamTerre Haute$28K
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.